The expression of CD86, a co-stimulatory molecule, resulted in the conversion of CAFs ("foe") to engineered CAFs ("friend") for processing and presenting tumor-associated antigens, which dramatically suppressed the progression of highly fibrotic 4T1 breast cancer in conjunction with PD-L1 blockade 340. Here, CD274 is linked to neoplasm.